The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Journal:
Current Pharmaceutical Biotechnology
Volume:
2
Page:
293-300
Author(s):
R.O. Dillman
Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Journal:
Current Pharmaceutical Biotechnology
Volume:
2
Page:
301-311
Author(s):
A. J. Grillo-Lopez, B.K. Dallaire, A. McClure, R. Weaver, C. Varns, A. Wei, R. Allen, D. Lee, D. Shen, J. Leonard, P.Multani and C.A.White
Toxin-Labeled Monoclonal Antibodies
Journal:
Current Pharmaceutical Biotechnology
Volume:
2
Page:
313-325
Author(s):
R.J. Kreitman
Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects
Journal:
Current Pharmaceutical Biotechnology
Volume:
2
Page:
351-356
Author(s):
M.G. Stabin and A.B. Brill
Future Approaches for Treating Hematologic Disease
Journal:
Current Pharmaceutical Biotechnology
Volume:
2
Page:
369-382
Author(s):
M. Reff, G. Braslawsky and N. Hanna
Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Journal:
Current Genomics
Volume:
2
Page:
325-335
Author(s):
R. Kappler and H. Scherthan
T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Journal:
Current Gene Therapy
Volume:
1
Page:
325-337
Author(s):
F. A. Ayuk, A. R. Zander and B. Fehse
Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Journal:
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Volume:
1
Page:
241-253
Author(s):
G. Ranieri and G. Gasparini
Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Journal:
Current Medicinal Chemistry - Anti-Cancer Agents
Volume:
1
Page:
313-329
Author(s):
Mira Susa, Markus Glatt and Anna Teti
Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Journal:
Current Medicinal Chemistry - Central Nervous System Agents
Volume:
1
Page:
171-199
Author(s):
Zafar H. israili